OBJECTIVE: This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. METHODS: Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18. RESULTS: An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α=0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. CONCLUSIONS: The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.
OBJECTIVE: This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. METHODS: Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18. RESULTS: An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α=0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. CONCLUSIONS: The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Kristina L Mirabeau-Beale; Alice B Kornblith; Richard T Penson; Hang Lee; Annekathryn Goodman; Susana M Campos; Linda Duska; Lauren Pereira; Jessica Bryan; Ursula A Matulonis Journal: Gynecol Oncol Date: 2009-05-28 Impact factor: 5.482
Authors: Andrea Luciani; Paul B Jacobsen; Martine Extermann; Paolo Foa; Desire Marussi; Janine A Overcash; Lodovico Balducci Journal: Am J Clin Oncol Date: 2008-10 Impact factor: 2.339
Authors: David Cella; Diane Paul; Susan Yount; Rodger Winn; Chih-Hung Chang; Donald Banik; Jane Weeks Journal: Cancer Invest Date: 2003 Impact factor: 2.176
Authors: Lari Wenzel; Helen Q Huang; David Cella; Chelsea O McKinney; Michael A Zevon; Jason A LaChance; Joan L Walker; Ritu Salani; Susan C Modesitt; Robert T Morris; William H Bradley; Matthew P Boente; Vivian E von Gruenigen Journal: Gynecol Oncol Date: 2021-09-20 Impact factor: 5.482
Authors: Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245
Authors: Mary H Sailors; Diane C Bodurka; Ibrahima Gning; Lois M Ramondetta; Loretta A Williams; Tito R Mendoza; Sonika Agarwal; Charlotte C Sun; Charles S Cleeland Journal: Gynecol Oncol Date: 2013-05-15 Impact factor: 5.482
Authors: Kristine A Donovan; Heidi S Donovan; David Cella; Martha E Gaines; Richard T Penson; Steven C Plaxe; Vivian E von Gruenigen; Deborah Watkins Bruner; Bryce B Reeve; Lari Wenzel Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Madeleine T King; Martin R Stockler; Rachel L O'Connell; Luke Buizen; Florence Joly; Anne Lanceley; Felix Hilpert; Aikou Okamoto; Eriko Aotani; Jane Bryce; Paul Donnellan; Amit Oza; Elisabeth Avall-Lundqvist; Jonathan S Berek; Jalid Sehouli; Amanda Feeney; Dominique Berton-Rigaud; Daniel S J Costa; Michael L Friedlander Journal: Qual Life Res Date: 2017-12-16 Impact factor: 4.147
Authors: Verena Meraner; Eva-Maria Gamper; Anna Grahmann; Johannes M Giesinger; Petra Wiesbauer; Monika Sztankay; Alain G Zeimet; Barbara Sperner-Unterweger; Bernhard Holzner Journal: BMC Cancer Date: 2012-02-28 Impact factor: 4.430
Authors: Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann Journal: Lancet Date: 2017-09-12 Impact factor: 79.321